Literature DB >> 9759548

Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.

J E Mickle1, G R Cutting.   

Abstract

Cystic fibrosis (CF) phenotypes are determined by mutations in the CF gene, genetic background, and environment. The nature of the cystic fibrosis transmembrane conductance regulator (CFTR) mutation determines the extent of protein function. CFTR mutations that abolish protein function are associated with severe CF phenotypes. Mutants that retain partial function of CFTR are associated with mild phenotypes. The effect of CFTR dysfunction is variable in different tissues. Atypical phenotypes caused by mutations in the CF gene may be revealed by CFTR mutation analysis and family studies. These phenotypes help to define the spectrum of clinical manifestations caused by CFTR mutations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759548     DOI: 10.1016/s0272-5231(05)70092-7

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  12 in total

1.  Cross-linking of ΔF508-CFTR promotes its trafficking to the plasma membrane.

Authors:  Karen Bernard; Kevin L Kirk
Journal:  Channels (Austin)       Date:  2010-07-23       Impact factor: 2.581

2.  Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27.

Authors:  Miquéias Lopes-Pacheco; Clément Boinot; Inna Sabirzhanova; Marcelo M Morales; William B Guggino; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2015-09-02       Impact factor: 5.157

3.  Late onset sporadic dilated cardiomyopathy caused by a cardiac troponin T mutation.

Authors:  Ana Morales; Jose Renato Pinto; Jill D Siegfried; Duanxiang Li; Nadine Norton; Mark Hofmeyer; Marta Vallin; Azorides R Morales; James D Potter; Ray E Hershberger
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

4.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

5.  Application of multiplex ARMS and SSCP/HD analysis in molecular diagnosis of cystic fibrosis in Indian patients.

Authors:  Tester F Ashavaid; Altaf A Kondkar; Alpa J Dherai; Rani Raghavan; Soonu V Udani; Zarir F Udwadia; Devendra Desai
Journal:  Mol Diagn       Date:  2005

6.  Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Edward Kloza; Elaine Sugarman; Barbara Pettersen; Trisha Brown; Kim Jensen; Seth Marcus; Joy Redman
Journal:  J Genet Couns       Date:  2005-02       Impact factor: 2.537

7.  A PDZ-interacting domain in CFTR is an apical membrane polarization signal.

Authors:  B D Moyer; J Denton; K H Karlson; D Reynolds; S Wang; J E Mickle; M Milewski; G R Cutting; W B Guggino; M Li; B A Stanton
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 8.  Validating therapeutic targets through human genetics.

Authors:  Robert M Plenge; Edward M Scolnick; David Altshuler
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

Review 9.  Atypical cystic fibrosis and CFTR-related diseases.

Authors:  Shruti M Paranjape; Pamela L Zeitlin
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 10.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.